Xilio reports FY2022 net loss $88.2M; cash $120.4M; XTX202 shows early tumor-selective activation

Xilio Therapeutics, Inc.

Cash and cash equivalents $120.4M as of Dec 31, 2022, down from $198.1M; cash runway into Q2 2024.
Net loss for FY2022 was $88.2M vs $75.8M in 2021; Q4 net loss $22.5M vs $19.7M.
XTX202 (tumor-activated IL-2) showed preliminary pharmacodynamic evidence of tumor-selective activation in two patients; no vascular leak syndrome observed.
XTX202 Phase 2 monotherapy trial in melanoma and RCC to initiate April 2023; preliminary Phase 1/2 data expected Q3 2023.
XTX101 (anti-CTLA-4) RP2D set at 150 mg Q6W; preliminary Phase 1 data expected Q2 2023; exploring partnership.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xilio Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 2, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-002685

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.